RE: Potential value of brain penetrant TYK2/JAK1 - Biohaven deal28 Apr 2025 11:49
To sad, and others, you wonder why there are some here that "indicate negativity towards development of another compound". Might it be the amount of time, and money, it's taken even to arrive at this juncture with 1801? Also, SRA737 is proving a hard sell, despite all the apparent promise. And from today's RNS: "The Company is assessing the potential next steps for these compounds, including whether to progress one or more into preclinical development." Preclinical development? Really? So we're back to square one now are we? Moreover: "While further optimisation is still required". Okay, so how long will that take? It does, as Potnak stated earlier, feel like a pivot (for whatever reason). I'm reminded of the whole AGILE RNS which was initially well-received and then turned into a damp squib. I really hope that I'm wrong on all this, but I'm sensing BoD smoke and mirrors from today's RNS.